Search Results - "Albrecht, J.K."

449 OVERALL SAFETY PROFILE OF BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN by Manns, M.P, Felizarta, F, Schiff, E, Burroughs, M, Sniukiene, V, Boparai, N, Brass, C.A, Albrecht, J.K, Vierling, J.M

Get full text

452 EFFICACY AMONG NORTH AMERICAN AND EUROPEAN HCV GENOTYPE-1 TREATMENT-NAIVE AND PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN by Marcellin, P, Vierling, J.M, Alric, L, Pirisi, M, Tran, A, Albrecht, J.K, Brass, C.A, Boparai, N, Sniukiene, V, Burroughs, M

Get full text

7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIES by Bruno, S, Vierling, J.M, Esteban, R, Nyberg, L.M, Tanno, H, Albrecht, J.K, Brass, C.A, Boparai, N, Sniukiene, V, Burroughs, M

Get full text

12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY by Poordad, F, Bronowicki, J.-P, Gordon, S.C, Zeuzem, S, Jacobson, I.M, Sulkowski, M.S, Poynard, T, Morgan, T.R, Burroughs, M, Sniukiene, V, Boparai, N, Brass, C.A, Albrecht, J.K, Bacon, B.R

Get full text

466 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 WHEN TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR) by Reddy, K.R, Bruno, S, Rossaro, L, Ravendhran, N, Pauly, M.P, Boparai, N, Sniukiene, V, Brass, C.A, Albrecht, J.K, Poordad, F, Jacobson, I.M

Get full text

428 ADHERENCE TO ASSIGNED DOSING REGIMEN AND SUSTAINED VIROLOGIC RESPONSE AMONG HEPATITIS C GENOTYPE 1 TREATMENT-NAIVE AND PEG/RIBAVIRIN TREATMENT-FAILURES TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN by Gordon, S.C, Lawitz, E.J, Bacon, B.R, Sulkowski, M.S, Yoshida, E.M, Davis, M, Boparai, N, Sniukiene, V, Burroughs, M, Brass, C.A, Albrecht, J.K, Reddy, K.R

Get full text

9 BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN by Zeuzem, S, Barnard, R.J, Howe, J.A, Ogert, R.A, Ralston, R, Boparai, N, Brass, C.A, Albrecht, J.K, Burroughs, M, Sniukiene, V, Poordad, F, Gordon, S.C, Jacobson, I.M

Get full text

2014 IMPROVED INFLAMMATORY ACTIVITY WITH LOW-DOSE PEGINTRON (PEG) MAINTENANCE THERAPY IN PRIOR NONRESPONDERS WITH METAVIR FIBROSIS SCORES (MFS) OF F2/F3: FINAL RESULTS FROM THE EPIC3 PROGRAM by Poynard, T, Bruix, J, Schiff, E, Diago, M, Berg, T, Moreno-Otero, R, Lyra, L.G, Carrilho, F.J, Boparai, N, Griffel, L, Burroughs, M, Brass, C, Albrecht, J.K

Get full text

127 PHOSPHODIESTERASE POLYMORPHISMS MAY BE ASSOCIATED WITH BASELINE THYROID STIMULATING HORMONE (TSH) AND PEGINTERFERON TREATMENT INDUCED HYPOTHYROIDISM IN PATIENTS WITH CHRONIC HEPATITIS C by Clark, P.J, Thompson, A.J, Zhu, M, Ge, D, Shianna, K, Tillmann, H.L, Patel, K, Urban, T, Singh, A, Sulkowski, M, Afdhal, N, Jacobson, I, Esteban, R, Poordad, F, Lawitz, E, McCone, J, Shiffman, M.L, Galler, G, Lee, W.M, Reindollar, R, King, J, Kwo, P, Ghalib, R, Freilich, B, Nyberg, L, Noviello, S, Bopari, N, Koury, K, Pedicone, L.D, Brass, C, Albrecht, J.K, Goldstein, D, McHutchison, J.G, Muir, A.J

Get full text

304 METABOLIC SYNDROME (MS) IS A NEGATIVE PREDICTOR OF TREATMENT OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE IDEAL STUDY by Sulkowski, M.S, King, J.W, Harrison, S.A, Rossaro, L, Hu, K.-Q, Lawitz, E.J, Schiffman, M.L, Muir, A.J, Galler, G.W, McCone, J, Nyberg, L.M, Lee, W.M, Ghalib, R, McHutchison, J.G, Noviello, S, Goteti, V.S, Albrecht, J.K, Brass, C.A

Get full text

413 FIBROTEST (FT) VALUE INDEPENDENTLY PREDICTS EARLY (EVR) AND SUSTAINED VIROLOGICAL RESPONSE (SVR) IN NON-RESPONDER PATIENTS RE-TREATED WITH PEGYLATED INTERFERON ALFA-2B (PEG-2B) AND RIBAVIRIN IN EPIC3 by Poynard, T, Schiff, E.R, Terg, R, Moreno-Otero, R, Flamm, S.L, Schmidt, W, Berg, T, Goncales, F.L, Heathcote, J.E, Diago, M, McGarrity, T, Bedossa, P, Zhou, H, Mukhopadhyay, P, Griffel, L.H, Burroughs, M, Brass, C.A, Albrecht, J.K

Get full text

49 PEGINTRON MAINTENANCE THERAPY IN CIRRHOTIC (METAVIR F4) HCV PATIENTS, WHO FAILED TO RESPOND TO INTERFERON/RIBAVIRN (IR) THERAPY: FINAL RESULTS OF THE EPIC3 CIRRHOSIS MAINTENANCE TRIAL by Bruix, J, Poynard, T, Colombo, M, Schiff, E, Reichen, J, Burak, K, Heathcote, E.J.L, Berg, T, Poo-Ramirez, J.-L, Mello, C. Brandao, Guenther, R, Niederau, C, Terg, R, Bopari, N, Harvey, J, Griffel, L.H, Burroughs, M, Brass, C.A, Albrecht, J.K

Get full text

2015 GENOME WIDE ANALYSIS OF PATIENTS FROM THE IDEAL STUDY IDENTIFIES A CAUSAL ROLE FOR ITPA GENETIC VARIATION IN RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA by Thompson, A.J, Fellay, J, Ge, D, Urban, T, Shianna, K, Sulkowski, M, Muir, A, Afdhal, N, Jacobson, I, Esteban, R, Poordad, F, Lawitz, E, Mc Cone, J, Shiffman, M, Galler, G, Lee, W, Reindollar, R, King, J, Kwo, P, Ghalib, R, Freilich, B, Nyberg, L, Patel, K, Tillmann, H, Noviello, S, Bopari, N, Koury, K, Pedicone, L, Brass, C, Albrecht, J.K, Goldstein, D, Mc Hutchison, J.G

Get full text

104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS by Schiff, E, Poordad, F, Jacobson, I, Flamm, S, Bacon, B, Lawitz, E, Gordon, S, McHutchison, J, Ghalib, R, Poynard, T, Sulkowski, M, Trepo, C, Rizzetto, M, Zeuzem, S, Marcellin, P, Mendez, P, Brass, C, Albrecht, J.K

Get full text

822 PLATELET COUNT PREDICTS SUSTAINED VIRAL RESPONSE (SVR) IN THE RE-TREATMENT OF PREVIOUS INTERFERON/RIBAVIRIN NON-RESPONDERS (NR): RESULTS FROM THE EPIC3 PROGRAM by Poynard, T, Schiff, E, Terg, R, Moreno-Otero, R, Flamm, S, Schmidt, W, Berg, T, Goncales Jr, F, Heathcote, J, Diego, M, McGarrity, T, Bedossa, P, Deng, W, Mukhopadhyay, P, Griffel, L, Burroughs, M, Brass, C, Albrecht, J.K

Get full text

988 SUSTAINED VIRAL RESPONSE (SVR) IS DEPENDENT ON BASELINE CHARACTERISTICS IN THE RETREATMENT OF PREVIOUS ALFA INTERFERON/RIBAVIRIN (I/R) NONRESPONDERS (NR): FINAL RESULTS FROM THE EPIC3 PROGRAM by Poynard, T, Schiff, E, Terg, R, Otero, R. Moreno, Flamm, S, Schmidt, W, Berg, T, Goncales, F, Heathcote, J, Diago, M, McGarrity, T, Bedossa, P, Deng, W, Mukhopadhyay, P, Griffel, L, Burroughs, M, Brass, C, Albrecht, J.K

Get full text

804 SUSTAINED VIROLOGIC RESPONSE AFTER PEGINTERFERON ALFA-2B AND RIBAVIRIN TREATMENT PREDICTS LONG-TERM CLEARANCE OF HCV AT 5-YEAR FOLLOW-UP by Manns, M, Lindsay, K.L, Gordon, S.C, Pockros, P.J, Haeussinger, D, Hadziyiannis, S, Schmidt, W, Jacobson, I, Barcena, R, Schiff, E, Shaikh, O.S, Bacon, B, Marcellin, P, Smith, C, McHutchison, J.G, Deng, W, Pedicone, L.D, Albrecht, J.K

Get full text

484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN by Zeuzem, S, Vierling, J.M, Esteban, R, Gibas, A.L, Pol, S, Boparai, N, Burroughs, M, Brass, C.A, Albrecht, J.K, Poordad, F

Get full text

1419 A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN by Poordad, F.F, Lawitz, E.J, Reddy, K.R, Afdhal, N.H, Hezode, C, Zeuzem, S, Lee, S.S, Calleja, J.L, Brown, R.S, Craxi, A, Wedemeyer, H, Deng, W, Koury, K, Boparai, N, Pedicone, L.D, Burroughs, M, Wahl, J, Brass, C.A, Albrecht, J.K, Sulkowski, M.S

Get full text

476 ANEMIA DURING TREATMENT WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN WITH OR WITHOUT BOCEPREVIR IS ASSOCIATED WITH HIGHER SVR RATES: ANALYSIS OF PREVIOUSLY UNTREATED AND PREVIOUS-TREATMENT-FAILURE PATIENTS by Sulkowski, M.S, Poordad, F, Manns, M.P, Bronowicki, J.-P, Reddy, K.R, Harrison, S.A, Afdhal, N.H, Boparai, N, Sniukiene, V, Burroughs, M, Albrecht, J.K, Brass, C.A, Jacobson, I.M

Get full text